Ardelyx Stock Drops Significantly After Opting Out of CMS Payment Program for Xphozah

Tuesday, 2 July 2024, 15:06
Ardelyx (ARDX) saw a sharp decline of 20% in its stock value on Tuesday as the company announced its choice not to seek inclusion of Xphozah in the CMS's TDAPA payment program. This decision has prompted market concerns and raised questions about the future revenue impact on Ardelyx. Investors are closely monitoring the implications of this development on the company's financial performance.
Seeking Alpha
Ardelyx Stock Drops Significantly After Opting Out of CMS Payment Program for Xphozah

Ardelyx Stock Plummets 20%

Ardelyx (ARDX) stock tumbled 20% Tuesday after the company said it has decided not to apply to include its drug Xphozah in the CMS's TDAPA payment program.

Market Reaction and Concerns

  • Investors are closely monitoring the implications on Ardelyx.
  • Future Revenue Impact: Questions arise about the potential financial repercussions.

Read more here.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe